Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Filgrastim 4Cyclophosphamide 4Etoposide 3Cytarabine 3Carboplatin 3Busulfan 3tipifarnib 2sargramostim 2Topotecan 2Sunitinib 2Prednisone 2Interferon-alpha 2Imatinib Mesylate 2Decitabine 2Cyclosporine 2Analgesia 2veliparib 1romidepsin 1iadademstat 1gamma-Globulins 1decitabine and cedazuridine drug combination 1belinostat 1aldesleukin 1Vorinostat 1Vitamin E 1Vincristine 1Thiotepa 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Primary Myelofibrosis × iadademstat × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡